Emerald Advisers, LLC Supernus Pharmaceuticals, Inc. Transaction History

Emerald Advisers, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$28.79 - $35.41 $7.01 Million - $8.63 Million	243,577 Added 348.46%	313,477 $10.6 Million
Q2 2022 Jul 29, 2022	BUY	$25.33 - $34.25 $1.77 Million - $2.39 Million	69,900 New	69,900 $2.02 Million
Q1 2018 Apr 26, 2018	SELL	$37.15 - $46.9 $20.5 Million - $25.9 Million	-552,942 Closed	0 $0
Q4 2017 Feb 05, 2018	SELL	$36.4 - $42.6 $1.93 Million - $2.26 Million	-52,978 Reduced 8.74%	552,942 $22 Million
Q3 2017 Oct 30, 2017	BUY	$36.75 - $49.65 $22.3 Million - $30.1 Million	605,920	605,920 $24.2 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.